Walvax Biotechnology Co., Ltd.
300142
Rang în acțiuni
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Preț acțiune
$1.87
Capitalizare de piață
$2.98B
Schimbare (1 zi)
-3.71%
Schimbare (1 an)
14.73%
Țară
CN
Tranzacționează Walvax Biotechnology Co., Ltd. (300142)
Categorie
Healthcare
Marja operațională pentru Walvax Biotechnology Co., Ltd. (300142)
Marja operațională la October 2026 TTM: 6.19%
Conform celor mai recente rapoarte financiare și prețului acțiunilor Walvax Biotechnology Co., Ltd., marja operațională curentă (TTM) este 6.19%. La finalul anului 2024, compania avea o marjă operațională de 3.43%.
Istoricul marjei operaționale pentru Walvax Biotechnology Co., Ltd. din 2007 până în 2026
Marja operațională la sfârșitul fiecărui an
| An | Marja Operațională | Schimbă |
|---|---|---|
| 2026 (TTM) | 6.19% | 113.45% |
| 2025 | 2.90% | -15.45% |
| 2024 | 3.43% | -77.01% |
| 2023 | 14.92% | -30.99% |
| 2022 | 21.62% | 5.41% |
| 2021 | 20.51% | -56.20% |
| 2020 | 46.83% | 125.47% |
| 2019 | 20.77% | 37.82% |
| 2018 | 15.07% | -169.87% |
| 2017 | -21.57% | -20.20% |
| 2016 | -27.03% | -69.72% |
| 2015 | -89.28% | -601.01% |
| 2014 | 17.82% | 2,870.00% |
| 2013 | 0.60% | -98.55% |
| 2012 | 41.43% | -17.52% |
| 2011 | 50.23% | 1.89% |
| 2010 | 49.30% | 32.21% |
| 2009 | 37.29% | 95.24% |
| 2008 | 19.10% | 338.07% |
| 2007 | 4.36% | 0.00% |
Marja operațională pentru companii similare sau concurente
| Companie | Marja Operațională | Diferență în marja operațională | Țara |
|---|---|---|---|
| 19.41% | -96.86% |
DE
|
|
| 19.68% | -96.82% |
DE
|
|
| 10.52% | -98.30% |
JP
|
|
| 17.08% | -97.24% |
CH
|
|
| 22.93% | -96.30% |
IN
|
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.